Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

摘要: Background The MEK inhibitor trametinib is currently undergoing clinical trials as the treatment of metastatic melanoma both alone and in combination with BRAF dabrafenib. One most frequent side-effects associated its use a single agent development acneiform eruptions. These eruptions seem to be reduced when dosed dabrafenib. Objectives To investigate prevalence patients taking trametinib, dabrafenib. Methods All enrolled (n = 13) or dabrafenib (n = 30) at site underwent retrospective file review. The management acne was noted. Results In total, 77% group developed an eruption on trial, while only 10% lesions trial. were treated oral doxycycline, topical antibiotics antiseptic washes, good response. However condition recurred if these treatments ceased patient still therapy. Conclusions The When combined frequency this side-effect reduced.